Skip to content
Thiothixene
Navane (thiothixene) is a small molecule pharmaceutical. Thiothixene was first approved as Navane on 1982-01-01. It is used to treat psychotic disorders, schizophrenia, and schizophrenia spectrum and other psychotic disorders in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 2A. In addition, it is known to target histamine H1 receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
mental disordersD001523
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Thiothixene
Tradename
Company
Number
Date
Products
NAVANEMylanN-016584 DISCN1982-01-01
5 products, RLD
Hide discontinued
Thiothixene hydrochloride
Tradename
Company
Number
Date
Products
NAVANEMylanN-016758 DISCN1982-01-01
1 products, RLD
NAVANEMylanN-016904 DISCN1982-01-01
2 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
thiothixeneANDA2023-04-03
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
psychotic disorders—D011618F20.81
schizophreniaEFO_0000692D012559F20
schizophrenia spectrum and other psychotic disorders—D019967—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N05: Psycholeptics
— N05A: Antipsychotics
— N05AF: Thioxanthene derivatives, antipsychotic
— N05AF04: Tiotixene
HCPCS
No data
Clinical
Clinical Trials
7 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SchizophreniaD012559EFO_0000692F20——1113
Psychotic disordersD011618F20.81———1—1
Schizophrenia spectrum and other psychotic disordersD019967———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DementiaD003704F03——1——1
Psychophysiologic disordersD011602F45.9——1——1
DepressionD003863F33.9——1——1
Anxiety disordersD001008EFO_0006788F41.1——1——1
Liver neoplasmsD008113EFO_1001513C22.0——1——1
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myeloid leukemia acuteD015470C92.01————1
Healthy volunteers/patients—1————1
Tick-borne encephalitisD004675EFO_1001309A841————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTHIOTHIXENE
INNtiotixene
Description
Thiothixene is a N-methylpiperazine. It has a role as an anticoronaviral agent.
Classification
Small molecule
Drug classTypical antipsychotic
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CN1CCN(CC/C=C2/c3ccccc3Sc3ccc(S(=O)(=O)N(C)C)cc32)CC1
Identifiers
PDB—
CAS-ID3313-26-6
RxCUI10510
ChEMBL IDCHEMBL1201
ChEBI ID—
PubChem CID941651
DrugBankDB01623
UNII ID7318FJ13YJ (ChemIDplus, GSRS)
Target
Agency Approved
HTR2A
HTR2A
Organism
Homo sapiens
Gene name
HTR2A
Gene synonyms
HTR2
NCBI Gene ID
3356
Protein name
5-hydroxytryptamine receptor 2A
Protein synonyms
5-HT2 receptor, 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled, serotonin 5-HT-2A receptor, Serotonin receptor 2A
Uniprot ID
Q5T8C0
Mouse ortholog
Htr2a (15558)
5-hydroxytryptamine receptor 2A (P35363)
Alternate
HRH1
HRH1
Organism
Homo sapiens
Gene name
HRH1
Gene synonyms
NCBI Gene ID
3269
Protein name
histamine H1 receptor
Protein synonyms
histamine receptor, subclass H1
Uniprot ID
Q6P9E5
Mouse ortholog
Hrh1 (15465)
histamine H1 receptor (Q91XN3)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 614 documents
View more details
Safety
Black-box Warning
Black-box warning for: Thiothixene
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
625 adverse events reported
View more details